Azaindoles

US7227020B2 · kind B2 · utility

Assignee

• AVENTIS PHARMA LIMITED · GB

Inventors

• Paul Cox · Romford, GB
• Tahir Majid · Hoboken, US
• Shelley Amendola · Bedminster, US
• Stephanie Deprets · Paris, FR
• Christoper David Edlin · Hitchin, GB
• Justine Lai · Blieskastel, DE
• Andrew David Morley · Cambridge, GB

Key dates

• Filing date: Apr 20, 2004
• Grant date: Jun 5, 2007
• Expiry date: Apr 20, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Chemical compositions containing physiologically active compounds of general formula (I):wherein R1 is aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z1R8, —C(═O)—NY3Y4, —CO2R8, —NY3Y4, —N(R6)—C(═O)—R7, —N(R6)—C(═O)—NY3Y4, —N(R6)—C(═O)—OR7, —N(R6)—SO2—R7, —N(R6)—SO2—NY3Y4 and one or more halogen atoms; R3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, —C(═O)—OR5 or —C(═O)—NY3Y; and X1 represents N, CH, C-halo, C—CN, C—R7, C—NY3Y4, C—OH, C-Z2R7, C—C(═O)—OR5, C—C(═O)—NY3Y4, C—N(R8)—C(═O)—R7, C—SO2—NY3Y4, C—N(R8)—SO2—R7, C-alkenyl, C-alkynyl or C—NO2; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I).Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.